These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
809 related articles for article (PubMed ID: 29536608)
1. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study. Montvida O; Shaw JE; Blonde L; Paul SK Diabetes Obes Metab; 2018 Jul; 20(7):1722-1731. PubMed ID: 29536608 [TBL] [Abstract][Full Text] [Related]
2. Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study. Rathmann W; Bongaerts B; Kostev K Diabetes Obes Metab; 2016 Aug; 18(8):840-3. PubMed ID: 27062643 [TBL] [Abstract][Full Text] [Related]
3. Treatment intensification for patients with type 2 diabetes and poor glycaemic control. Fu AZ; Sheehan JJ Diabetes Obes Metab; 2016 Sep; 18(9):892-8. PubMed ID: 27160505 [TBL] [Abstract][Full Text] [Related]
4. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes. Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380 [TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England. Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618 [TBL] [Abstract][Full Text] [Related]
6. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study. Mamza J; Mehta R; Donnelly R; Idris I Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210 [TBL] [Abstract][Full Text] [Related]
7. Third-Line Antidiabetic Therapy Intensification Patterns and Glycaemic Control in Patients with Type 2 Diabetes in the USA: A Real-World Study. Koye DN; Montvida O; Paul SK Drugs; 2020 Apr; 80(5):477-487. PubMed ID: 32141024 [TBL] [Abstract][Full Text] [Related]
8. Factors Associated with Type 2 Diabetes Mellitus Treatment Choice Across Four European Countries. Heintjes EM; Overbeek JA; Hall GC; Prieto-Alhambra D; Lapi F; Hammar N; Bezemer ID Clin Ther; 2017 Nov; 39(11):2296-2310.e14. PubMed ID: 29108837 [TBL] [Abstract][Full Text] [Related]
9. Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study. Patorno E; Everett BM; Goldfine AB; Glynn RJ; Liu J; Gopalakrishnan C; Kim SC Diabetes Obes Metab; 2016 Aug; 18(8):755-65. PubMed ID: 27003762 [TBL] [Abstract][Full Text] [Related]
10. Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes. Montvida O; Shaw J; Atherton JJ; Stringer F; Paul SK Diabetes Care; 2018 Jan; 41(1):69-78. PubMed ID: 29109299 [TBL] [Abstract][Full Text] [Related]
11. Glucagon-like-peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes in diabetes in relation to achieved glycemic control. A Danish nationwide study. Zareini B; Sørensen KK; Pedersen-Bjergaard U; Loldrup Fosbøl E; Køber L; Torp-Pedersen C J Diabetes; 2024 Jun; 16(6):e13560. PubMed ID: 38751369 [TBL] [Abstract][Full Text] [Related]
12. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study. Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337 [TBL] [Abstract][Full Text] [Related]
13. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. Alvarez Guisasola F; Mavros P; Nocea G; Alemao E; Alexander CM; Yin D Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():8-15. PubMed ID: 18435669 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of Outcomes After Initiating Triple Antidiabetic Therapy with a GLP-1 RA in an Integrated Health Care System. Lee SM; Aboubechara N; Niu F; Ledesma VM; Patel YA; Millares M; Hui RL J Manag Care Spec Pharm; 2019 Mar; 25(3):350-356. PubMed ID: 30816819 [TBL] [Abstract][Full Text] [Related]
15. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting. Chakravarty A; Rastogi M; Dhankhar P; Bell KF J Med Econ; 2018 May; 21(5):497-509. PubMed ID: 29376760 [TBL] [Abstract][Full Text] [Related]
16. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes. Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794 [TBL] [Abstract][Full Text] [Related]
17. Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients. Montvida O; Klein K; Kumar S; Khunti K; Paul SK Diabetes Obes Metab; 2017 Jan; 19(1):108-117. PubMed ID: 27629433 [TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919 [TBL] [Abstract][Full Text] [Related]
19. Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany. Khunti K; Godec TR; Medina J; Garcia-Alvarez L; Hiller J; Gomes MB; Cid-Ruzafa J; Charbonnel B; Fenici P; Hammar N; Hashigami K; Kosiborod M; Nicolucci A; Shestakova MV; Ji L; Pocock S Diabetes Obes Metab; 2018 Feb; 20(2):389-399. PubMed ID: 28817227 [TBL] [Abstract][Full Text] [Related]
20. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study. Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]